Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trialParesh Dandona, Bertrand Cariou, Chantal Mathieu et al.|The Lancet Diabetes & Endocrinology|2017Cited by 295
Effects of Semaglutide With or Without Concomitant Mineralocorticoid Receptor Antagonist Use in Participants With Type 2 Diabetes and Chronic Kidney Disease: A FLOW Trial Prespecified Secondary AnalysisPeter Rossing, Márcio Krakauer, Katherine R. Tuttle et al.|Diabetes Care|2025Cited by 16